Glioma: An overview of current classifications, characteristics, molecular biology and target therapies

Frontiers in Bioscience - Landmark

Volumn 20, Issue 7, 2015, Pages 1104-1115

  Zeng, Tao ^a   Cui, Daming ^a   Gao, Liang ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Glioblastomas; Glioma; Molecular biology; Target therapies

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; PTEN PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN;

ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MODELS, MOLECULAR; PLATELET-DERIVED GROWTH FACTOR; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929154261     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4362     Document Type: Review

References (96)

1. P. de Robles, K. M. Fiest, A. D. Frolkis, T. Pringsheim, C. Atta, C. St Germaine-Smith: The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol (2014) DOI: 10.1093/neuonc/nou283
2. Q. T. Ostrom, H. Gittleman, P. Liao, C. Rouse, Y. Chen, J. Dowling, Y. Wolinsky, C. Kruchko and J. Barnholtz-Sloan: CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol (2014) DOI: 10.1093/neuonc/nou223
3. S. Takahashi: (2. Diseases of the brain 2: brain tumors). Nihon Hoshasen Gijutsu Gakkai Zasshi 70(9), 1095-105 (2014) DOI: 10.6009/jjrt.2014-JSRT-70.9.1095
4. B. Shofty, S. Constantini, F. Bokstein, Z. Ram, L. Ben-Sira, S. Freedman, G. Vainer: Optic pathway gliomas in adults. Neurosurgery 74(3), 273-9 (2013) DOI: 10.1227/NEU.0000000000000257
5. T. Schneider, C. Mawrin, C. Scherlach, M. Skalej and R. Firsching: Gliomas in adults. Dtsch Arztebl Int 107(45), 799-807 (2010) Doi not found
6. P. Y. Wen and S. Kesari: Malignant gliomas in adults. N Engl J Med 359(5), 492-507 (2008) DOI: 10.1056/NEJMra0708126
7. M. L. Goodenberger and R. B. Jenkins: Genetics of adult glioma. Cancer Genet 205(12), 613-21 (2012) DOI: 10.1016/j.cancergen.2012.10.009
8. J. P. Posti, M. Bori, T. Kauko, M. Sankinen, J. Nordberg, M. Rahi, J. Frantzen, V. Vuorinen: Presenting symptoms of glioma in adults. Acta Neurol Scand (2014) DOI: 10.1111/ane.12285
9. E. M. Sizoo, L. Braam, T. J. Postma, H. R. Pasman, J. J. Heimans, M. Klein: Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 12(11), 1162-6 (2010) DOI: 10.1093/neuonc/nop045
10. N. Yamaguchi: (The IARC carcinogenicity evaluation of radio-frequency electromagnetic field: with special reference to epidemiology of mobile phone use and brain tumor risk). Nihon Eiseigaku Zasshi 68(2), 78-82 (2013) DOI: 10.1265/jjh.68.78
11. V. S. Benson, K. Pirie, J. Schuz, G. K. Reeves, V. Beral and J. Green: Mobile phone use and risk of brain neoplasms and other cancers: prospective study. Int J Epidemiol 42(3), 792-802 (2010) DOI: 10.1093/ije/dyt072
12. C. O. Da Fonseca, J. T. Silva, I. R. Lins, M. Simao, A. Arnobio, D. Futuro: Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs 27(6), 557-64 (2009) DOI: 10.1007/s10637-008-9215-3
13. K. M. Kurian, H. R. Haynes, C. Crosby, K. Hopkins and M. Williams: IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker. Br J Neurosurg 27(4), 442-5 (2013) DOI: 10.3109/02688697.2013.771139
14. K. Ichimura: Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 29(3), 131-9 (2012) DOI: 10.1007/s10014-012-0090-4
15. G. Lombardi, A. Della Puppa, A. L. Di Stefano, A. Pace, R. Ruda, E. Tabouret and V. Zagonel: Gliomas. Biomed Res Int (2014) Doi not found
16. S. Trabelsi, D. H. Brahim, M. Ladib, N. Mama, I. Harrabi, K. Tlili: Glioma epidemiology in the central tunisian population: 1993-2012. Asian Pac J Cancer Prev 15(20), 8753-7 (2014) Doi not found
17. Q. T. Ostrom, L. Bauchet, F. G. Davis, I. Deltour, J. L. Fisher, C. E. Langer: The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16(7), 896-913 (2014) DOI: 10.1093/neuonc/nou087
18. J. Rineer, D. Schreiber, K. Choi and M. Rotman: Characterization and outcomes of infratentorial malignant glioma: a populationbased study using the Surveillance Epidemiology and End-Results database. Radiother Oncol 95(3), 321-6 (2010) DOI: 10.1016/j.radonc.2010.04.007
19. W. Wick and M. Weller: Classification and management of anaplastic gliomas. Curr Opin Neurol 22(6), 650-6 (2009) DOI: 10.1097/WCO.0b013e3283329ce7
20. D. Figarella-Branger, C. Colin, B. Coulibaly, B. Quilichini, A. Maues De Paula, C. Fernandez: (Histological and molecular classification of gliomas). Rev Neurol (Paris) 164(6-7), 505-15 (2008) DOI: 10.1016/j.neurol.2008.03.011
21. A. Araque and M. Navarrete: Glial cells in neuronal network function. Philos Trans R Soc Lond B Biol Sci,365(1551), 2375-81 (2009) DOI: 10.1098/rstb.2009.0313
22. E. Lopez-Bayghen and A. Ortega: (Glial cells and synaptic activity: translational control of metabolic coupling). Rev Neurol 50(10), 607-15 (2010) Doi not found
23. Y. Li, X. F. Du and J. L. Du: (Physiological properties and functions of microglia). Sheng Li Xue Bao 65(5), 471-82 (2013) Doi not found
24. H. Wake, A. J. Moorhouse and J. Nabekura: Functions of microglia in the central nervous system - beyond the immune response. Neuron Glia Biol 7(1), 47-53 (2012) DOI: 10.1017/S1740925X12000063
25. A. S. Harms, J. K. Lee, T. A. Nguyen, J. Chang, K. M. Ruhn, I. Trevino: Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60(2), 189-202 (2011) DOI: 10.1002/glia.21254
26. L. B. Buckman and K. L. Ellacott: The contribution of hypothalamic macroglia to the regulation of energy homeostasis. Front Syst Neurosci 8, 212 (2014) DOI: 10.3389/fnsys.2014.00212
27. A. Hafidi and D. Galifianakis: Macroglia distribution in the developing and adult inferior colliculus. Brain Res Dev Brain Res 143(2), 167-77 (2003) DOI: 10.1016/S0165-3806(03)00110-X
28. M. J. Ramirez-Exposito and J. M. Martinez- Martos: (Structure and functions of the macroglia in the central nervous system. Response to degenerative disorders). Rev Neurol 26(152), 600-11 (1998) Doi not found
29. F. Lefranc, M. Rynkowski, O. DeWitte and R. Kiss: Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg 34, 3-35 (2009) DOI: 10.1007/978-3-211-78741-0-1
30. F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21(21), 2683-710 (2007) DOI: 10.1101/gad.1596707
31. A. Pusateri and C. E. Margo: Intraocular astrocytoma and its differential diagnosis. Arch Pathol Lab Med 138(9), 1250-4 (2013) DOI: 10.5858/arpa.2013-0448-RS
32. V. Suri, P. Jha, S. Agarwal, P. Pathak, M. C. Sharma, V. Sharma: Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 13(10), 1099-106 (2011) DOI: 10.1093/neuonc/nor146
33. F. Zustovich, A. Della Puppa, R. Scienza, P. Anselmi, C. Furlan and G. Cartei: Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien) 150(7), 699-702; discussion 702-3 (2008) DOI: 10.1007/s00701-008-1507-z
34. J. E. Bromberg and M. J. van den Bent: Oligodendrogliomas: molecular biology and treatment. Oncologist 14(2), 155-63 (2009) DOI: 10.1634/theoncologist.2008-0248
35. P. C. McCormick: Ependymomas. J Neurosurg Spine 19(1), 1-2 (2013) DOI: 10.3171/2013.1.SPINE121111
36. S. J. Baloyannis and I. S. Baloyannis: The fine structure of ependymomas. CNS Oncol 3(1), 49-59 (2014) DOI: 10.2217/cns.13.64
37. C. Bettegowda, O. Adogwa, V. Mehta, K. L. Chaichana, J. Weingart, B. S. Carson: Treatment of choroid plexus tumors: a 20-year single institutional experience. J Neurosurg Pediatr 10(5), 398-405 (2012) DOI: 10.3171/2012.8.PEDS12132
38. A. E. Gozali, B. Britt, L. Shane, I. Gonzalez, F. Gilles, J. G. McComb, M. D. Krieger: Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 58(6), 905-9 (2011) DOI: 10.1002/pbc.23349
39. D. R. Laks, K. Visnyei and H. I. Kornblum: Brain tumor stem cells as therapeutic targets in models of glioma. Yonsei Med J 51(5), 633-40 (2010) DOI: 10.3349/ymj.2010.51.5.633
40. A. Rousseau, K. Mokhtari and C. Duyckaerts: The 2007 WHO classification of tumors of the central nervous system - what has changed? Curr Opin Neurol 21(6), 720-7 (2008) DOI: 10.1097/WCO.0b013e328312c3a7
41. Q. Zhou: [WHO classification of tumors of central nervous system (2007): an introduction). Zhonghua Bing Li Xue Za Zhi 37(1), 5-7] (2008)
42. D. N. Louis, H. Ohgaki, O. D. Wiestler, W. K. Cavenee, P. C. Burger, A. Jouvet: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2), 97-109 (2007) DOI: 10.1007/s00401-007-0243-4
43. S. K. Carlsson, S. P. Brothers and C. Wahlestedt: Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 6(11), 1359-1370 (2013) DOI: 10.15252/emmm.201302627
44. H. Cholewa, K. Duda, K. Labuzek and B. Okopien: (The newest perspectives on the treatment of glioblastoma multiforme). Pol Merkur Lekarski 37(218), 119-23 (2014) Doi not found
45. Y. Zhang, Y. Pan and X. Li: Glioblastoma multiforme in the brainstem in a young adult. Clin Neurol Neurosurg, 124, 175-8 (2014) DOI: 10.1016/j.clineuro.2014.06.039
46. T. Scarabino, G. M. Giannatempo, F. Nemore, T. Popolizio and A. Stranieri: Supratentorial low-grade gliomas. Neuroradiology. J Neurosurg Sci, 49(3), 73-6 (2005) Doi not found
47. T. Miwa, Y. Hirose, H. Sasaki, E. Ikeda, K. Yoshida and T. Kawase: Genetic characterization of adult infratentorial gliomas. J Neurooncol, 91(3), 251-5 (2009) DOI: 10.1007/s11060-008-9714-2
48. M. H. Handler and N. K. Foreman: Pontine gliomas. J Neurosurg Pediatr 5(1), 140-1 (2009) DOI: 10.3171/2009.5.PEDS09265
49. I. Pascual-Castroviejo, A. Martinez Bermejo, V. Lopez Martin, C. Roche and S. I. Pascual Pascual: Optic gliomas in neurofibromatosis type 1 (NF-1). Presentation of 31 cases. Neurologia 9(5), 173-7 (1994) Doi not found
50. E. Hewer, L. Mariani and I. Vajtai: Glioma-like proliferation in a cortical hamartoma of tuberous sclerosis complex. Brain Tumor Pathol (2014) DOI: 10.1007/s10014-014-0185-1
51. I. Fischer, C. Cunliffe, R. J. Bollo, H. L. Weiner, O. Devinsky, M. E. Ruiz-Tachiquin, T. Venuto, A. Pearlman, L. Chiriboga, R. J. Schneider, H. Ostrer and D. C. Miller: Glioma-like proliferation within tissues excised as tubers in patients with tuberous sclerosis complex. Acta Neuropathol 116(1), 67-77 (2008) DOI: 10.1007/s00401-008-0391-1
52. E. J. Uhlmann and S. R. Plotkin: Neurofibromatoses. Adv Exp Med Biol 724, 266-77 (2012) DOI: 10.1007/978-1-4614-0653-2-20
53. M. J. Rabito and A. D. Kaye: Tuberous sclerosis complex: perioperative considerations. Ochsner J 14(2), 229-39 (2014) Doi not found
54. P. Virag, I. Brie, E. Fischer-Fodor, M. Perde-Schrepler, C. Tatomir, O. Balacescu: Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance. Cell Biochem Funct 29(5), 351-5 (2011) DOI: 10.1002/cbf.1754
55. K. Iwai, S. Adachi, M. Takahashi, L. Moller, T. Udagawa, S. Mizuno and I. Sugawara: Early oxidative DNA damages and late development of lung cancer in diesel exhaust-exposed rats. Environ Res 84(3), 255-64 (2000) DOI: 10.1006/enrs.2000.4072
56. G. Yuan, D. Gao, S. Ding and J. Tan: DNA repair gene ERCC1 polymorphisms may contribute to the risk of glioma. Tumour Biol 35(5), 4267-75 (2014) DOI: 10.1007/s13277-013-1557-6
57. P. Rajaraman, A. Hutchinson, S. Wichner, P. M. Black, H. A. Fine, J. S. Loeffler: DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 12(1), 37-48 (2010) DOI: 10.1093/neuonc/nop012
58. V. Milinkovic, J. Bankovic, M. Rakic, N. Milosevic, T. Stankovic, M. Jokovic: Genomic instability and p53 alterations in patients with malignant glioma. Exp Mol Pathol 93(2), 200-6 (2012) DOI: 10.1016/j.yexmp.2012.05.010
59. C. D. James: p53 in malignant glioma: 20 years later and still much to learn. Neuro Oncol, 12(5), 421 (2010) Doi not found
60. M. K. Sibin, D. I. Bhat, C. Lavanya, M. J. Manoj, S. Aakershita and G. K. Chetan: CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients. Tumour Biol 35(2), 1467-72 (2013) DOI: 10.1007/s13277-013-1201-5
61. C. Hartmann, L. Kluwe, M. Lucke and M. Westphal: The rate of homozygous CDKN2A/ p16 deletions in glioma cell lines and in primary tumors. Int J Oncol 15(5), 975-82 (1999) Doi not found
62. N. Ishii, D. Maier, A. Merlo, M. Tada, Y. Sawamura, A. C. Diserens: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9(3), 469-79 (1999) DOI: 10.1111/j.1750-3639.1999.tb00536.x
63. N. Senzer, J. Nemunaitis, M. Nemunaitis, J. Lamont, M. Gore, H. Gabra: p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 6(5), 1478-82 (2007) DOI: 10.1158/1535-7163.MCT-07-0125
64. L. S. Steelman, W. H. Chappell, S. L. Abrams, R. C. Kempf, J. Long, P. Laidler: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3(3), 192-222 (2011) Doi not found
65. H. J. Lim, P. Crowe and J. L. Yang: Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) DOI: 10.1007/s00432-014-1803-3
66. G. A. Alexiou and S. Voulgaris: The role of the PTEN gene in malignant gliomas. Neurol Neurochir Pol 44(1), 80-6 (2010) DOI: 10.1016/S0028-3843(14)60408-4
67. C. B. Knobbe, A. Merlo and G. Reifenberger: Pten signaling in gliomas. Neuro Oncol 4(3), 196-211 (2002) DOI: 10.1215/15228517-4-3-196
68. J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney: Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 9(3), 271-9 (2007) DOI: 10.1215/15228517-2007-003
69. Y. Yang, N. Shao, G. Luo, L. Li, L. Zheng, P. Nilsson-Ehle and N. Xu: Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate. Anticancer Res 30(3), 981-5 (2010) Doi not found
70. D. A. Hilton, M. Penney, B. Evans, H. Sanders and S. Love: Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol 26(4), 472-8 (2002) DOI: 10.1097/00000478-200204000-00009
71. J. W. Henson, B. L. Schnitker, K. M. Correa, A. von Deimling, F. Fassbender, H. J. Xu: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36(5), 714-21 (1994) DOI: 10.1002/ana.410360505
72. J. N. Rich, C. Guo, R. E. McLendon, D. D. Bigner, X. F. Wang and C. M. Counter: A genetically tractable model of human glioma formation. Cancer Res 61(9), 3556-60 (2001) Doi not found
73. Y. Yarden: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4, S3-8 (2001) DOI: 10.1016/S0959-8049(01)00230-1
74. T. A. Libermann, H. R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq: Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl 3, 161-72 (1985) DOI: 10.1242/jcs.1985.Supplement-3.16
75. J. L. Nakamura: The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications. Expert Opin Ther Targets 11(4), 463-72 (2007) DOI: 10.1517/14728222.11.4.463
76. M. T. Stockhausen, H. Broholm, M. Villingshoj, M. Kirchhoff, T. Gerdes, K. Kristoffersen: Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res 317(11), 1513-26 (2011) DOI: 10.1016/j.yexcr.2011.04.001
77. R. Altieri, A. Agnoletti, F. Quattrucci, D. Garbossa, F. M. Calamo Specchia, M. Bozzaro: Molecular biology of gliomas: present and future challenges. Transl Med UniSa 10, 29-37 (2014) Doi not found
78. J. Paulsson, M. Ehnman and A. Ostman: PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol 10(9), 1695-708 (2014) DOI: 10.2217/fon.14.83
79. N. Lindberg and E. C. Holland: PDGF in gliomas: more than just a growth factor? Ups J Med Sci 117(2), 92-8 (2012) DOI: 10.3109/03009734.2012.654860
80. A. Mauro, A. Bulfone, E. Turco and D. Schiffer: Coexpression of platelet-derived growth factor (PDGF) B chain and PDGF B-type receptor in human gliomas. Childs Nerv Syst 7(8), 432-6 (1991) DOI: 10.1007/BF00263184
81. K. E. Yen and D. P. Schenkein: Cancer-associated isocitrate dehydrogenase mutations. Oncologist, 17(1), 5-8 (2012) DOI: 10.1634/theoncologist.2011-0429
82. M. Megova, J. Drabek, V. Koudelakova, R. Trojanec, O. Kalita and M. Hajduch: Isocitrate dehydrogenase 1 and 2 mutations in gliomas. J Neurosci Res 92(12), 1611-20 (2014) DOI: 10.1002/jnr.23456
83. L. Yu, S. T. Qi and Z. Y. Li: Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas. Chin Med J (Engl) 123(24), 3697-705 (2011) Doi not found
84. C. Guo, C. J. Pirozzi, G. Y. Lopez and H. Yan: Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol 24(6), 648-52 (2011) DOI: 10.1097/WCO.0b013e32834cd415
85. G. Minniti, V. De Sanctis, R. Muni, F. Filippone, A. Bozzao, M. Valeriani: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88(1), 97-103 (2008) DOI: 10.1007/s11060-008-9538-0
86. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10), 987-96 (2005) DOI: 10.1056/NEJMoa043330
87. M. D. Prados, S. M. Chang, N. Butowski, R. DeBoer, R. Parvataneni, H. Carliner: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27(4), 579-84 (2009) DOI: 10.1200/JCO.2008.18.9639
88. M. J. van den Bent, A. A. Brandes, R. Rampling, M. C. Kouwenhoven, J. M. Kros, A. F. Carpentier: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27(8), 1268-74 (2009) DOI: 10.1200/JCO.2008.17.5984
89. J. H. Sampson, G. E. Archer, D. A. Mitchell, A. B. Heimberger, J. E. Herndon,: An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8(10), 2773-9 (2009) DOI: 10.1158/1535-7163.MCT-09-0124
90. J. H. Sampson, A. B. Heimberger, G. E. Archer, K. D. Aldape, A. H. Friedman, H. S. Friedman: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28(31), 4722-9 (2010) DOI: 10.1200/JCO.2010.28.6963
91. D. Sia, C. Alsinet, P. Newell and A. Villanueva: VEGF signaling in cancer treatment. Curr Pharm Des 20(17), 2834-42 (2013) DOI: 10.2174/13816128113199990590
92. L. W. Buie and J. Valgus: Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 42(10), 1486-90 (2008) DOI: 10.1345/aph.1L030
93. J. J. Vredenburgh, A. Desjardins, J. E. Herndon, 2nd, J. Marcello, D. A. Reardon, J. A. Quinn: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30), 4722-9 (2007) DOI: 10.1200/JCO.2007.12.2440
94. D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Gururangan, J. H. Sampson, S. Sathornsumetee, R. E. McLendon: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101(12), 1986-94 (2009) DOI: 10.1038/sj.bjc.6605412
95. N. Kannan, L. V. Nguyen and C. J. Eaves: Integrin beta3 links therapy resistance and cancer stem cell properties. Nat Cell Biol 16(5), 397-9 (2014) DOI: 10.1038/ncb2960
96. R. Stupp, M. E. Hegi, B. Neyns, R. Goldbrunner, U. Schlegel, P. M. Clement: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16), 2712-8 (2010) DOI: 10.1200/JCO.2009.26.6650